Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning Guardant Health’s 10-K can feel like wading through both biotech jargon and accounting footnotes. Key details on liquid biopsy test volumes, FDA submissions, and R&D burn rates are scattered across hundreds of pages, while Form 4 insider sales from the founders often appear without context. If you have ever searched “Guardant Health SEC filings explained simply” or asked, “Where can I find the Guardant Health quarterly earnings report 10-Q filing?”, you know the challenge.
Stock Titan solves it. Our AI-powered summaries translate dense cancer-genomics language into clear insights, flagging segment revenue shifts and clinical milestone disclosures in seconds. Need real-time alerts? The moment a “Guardant Health Form 4 insider transactions real-time” filing hits EDGAR, we surface it alongside easy-to-read charts of executive stock transactions. Drill into any document:
- Guardant Health annual report 10-K simplified – spot test-volume growth and cash runway.
- Guardant Health quarterly earnings report 10-Q filing – track sequential margin changes.
- Guardant Health 8-K material events explained – catch trial results or reimbursement wins.
- Guardant Health proxy statement executive compensation – review R&D-weighted incentive plans.
Whether you’re modeling future oncology revenues or monitoring “Guardant Health earnings report filing analysis” for competitive intelligence, Stock Titan provides AI guidance that saves hours. Join institutional investors who are already “understanding Guardant Health SEC documents with AI” to make informed decisions faster.
Guardant Health (GH) filed its Q3 2025 10-Q, reporting higher revenue and a narrower loss. Revenue rose to $265,196,000 from $191,476,000 a year ago, while net loss improved to $92,725,000 from $107,754,000. Loss per share was $0.74 versus $0.88.
Growth was broad-based: Oncology revenue was $184,402,000, Biopharma and data $54,731,000, Screening $24,112,000, and Licensing and other $1,951,000. For the nine months, revenue totaled $700,755,000, with a net loss of $287,783,000.
Cash and cash equivalents were $580,013,000, with restricted cash of $109,502,000; total assets were $1,276,786,000. Operating cash outflow for the nine months was $158,387,000. The company exchanged $659,300,000 of 2027 notes for $600,000,000 of 1.25% notes due 2031, recording a $13,672,000 gain and leaving $490,700,000 of 2027 notes outstanding. Treasury stock repurchases were $45,010,000 for 976,351 shares. As of October 24, 2025, 126,041,089 common shares were outstanding.
Guardant Health (GH) reported an insider equity change. Director Roberto A. Mignone had 3,167 shares of Common Stock acquired on 10/21/2025 via a code M transaction, reflecting the conversion of restricted stock units at a price of $0.
Following the transaction, the filing lists 3,167 Common Stock shares beneficially owned in direct form. The derivative table shows 9,504 Restricted Stock Units beneficially owned after the event. The RSU grant from November 8, 2024 vests over four years: 25% on the one-year anniversary of October 21, 2024, with the remaining 75% vesting monthly over the next three years.
Guardant Health (GH) director Manuel Hidalgo Medina reported the vesting and settlement of restricted stock units into 232 shares of Common Stock on 10/17/2025 (transaction code M) at $0 per share.
Following the transaction, he directly owned 1,315 shares of Common Stock and held 7,657 RSUs outstanding. The RSU grant dated July 17, 2024 vests over four years: 25% vested on the one-year anniversary of July 17, 2024, with the remaining 75% vesting monthly over the next three years.
Guardant Health (GH) reported an insider transaction on a Form 4. A company director sold 116 shares of common stock at $66.95 on 10/17/2025. Following the sale, the reporting person directly holds 7,725 shares.
Guardant Health (GH) filed a Form 4 disclosing an insider sale. Director Myrtle S. Potter sold 26 shares of common stock on 10/17/2025 at $66.95 per share. After this transaction, she directly beneficially owns 18,324 shares. The filing lists the ownership form as direct and does not report any derivative security activity.
Guardant Health (GH)October 15, 2025, 69 shares of Common Stock were acquired at $0 upon the vesting and settlement of Restricted Stock Units (RSUs) (transaction code M). Following this, the director directly owned 18,350 shares.
The RSU award vested 25% on October 15, 2022, with the remaining 75% vesting in substantially equal monthly installments over the next three years.
Guardant Health (GH) director reports Form 4 activity. On 10/15/2025, 250 shares of common stock were acquired at $0 following the settlement of restricted stock units (transaction code M). After this transaction, the reporting person directly owns 7,841 shares.
The related derivative line shows 250 restricted stock units converted into 250 shares at $0 on 10/15/2025, leaving 4,248 derivative securities (restricted stock units) directly beneficially owned after the event.
The award referenced in the footnotes was granted on March 6, 2023 and vests over four years: 25% vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the following three years.
Chris Freeman, Chief Commercial Officer of Guardant Health, Inc. (GH), reported multiple equity transactions dated 10/01/2025. He had 13,550 restricted stock units vest or be credited (1,928; 1,668; 9,954) and a separate purchase of 5,740 shares at $62.65. The company retained 5,740 shares to satisfy the tax withholding related to one vesting installment; the filer notes the retained amount did not exceed the tax liability. Following the reported transactions, Freeman beneficially owned 63,179 shares (direct ownership). The Form 4 was signed by an attorney-in-fact on behalf of Mr. Freeman on 10/02/2025.
Guardant Health director and Co‑Chief Executive Officer AmirAli Talasaz reported multiple transactions in the company's common stock. On 09/30/2025 he received 4,814 shares from vesting of restricted stock units and, separately the same day, 2,440 shares were retained by the company to satisfy tax withholding at a reported price of $62.48. On 10/01/2025 he received an additional 23,997 vested shares and 12,162 shares were retained for tax withholding at $62.65. After these reported transactions his beneficial ownership rose to 2,010,036 shares.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
